FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2948570007> ?p ?o ?g. }

• W2948570007 endingPage "l2211" @default.
• W2948570007 startingPage "l2211" @default.
• W2948570007 abstract "Abstract Objective To test the hypothesis that ticagrelor plus aspirin is safe and superior to clopidogrel plus aspirin for reducing high platelet reactivity at 90 days and stroke recurrence in patients with minor stroke or transient ischaemic attack, particularly in carriers of the CYP2C19 loss-of-function allele and patients with large artery atherosclerosis. Design Open label, blinded endpoint, randomised controlled phase II trial. Setting Prospective studies conducted at 26 centres in China, August 2015 to March 2017. Participants 675 patients with acute minor stroke or transient ischaemic attack. Intervention Ticagrelor (180 mg loading dose, 90 mg twice daily thereafter) or clopidogrel (300 mg loading dose, 75 mg daily thereafter) on a background of aspirin (100 mg daily for the first 21 days) within 24 hours of symptom onset. Main outcome measures Primary outcome was the proportion of patients with high platelet reactivity at 90 days. High platelet reactivity was defined as P2Y12 reaction units of more than 208. Secondary outcomes included high platelet reactivity at 90 days (7 days either way) in patients carrying genetic variants that would affect clopidogrel metabolism, and any stroke (ischaemic or haemorrhagic) recurrence at 90 days (7 days either way), six months, and one year. Results At 90 days, high platelet reactivity occurred in 35 (12.5%) of 280 patients in the ticagrelor/aspirin group and 86 (29.7%) of 290 patients in the clopidogrel/aspirin group (risk ratio 0.40; 95% confidence interval 0.28 to 0.56; P<0.001), and in 10.8% versus 35.4% (0.31; 0.18 to 0.49; P<0.001) of patients carrying CYP2C19 loss-of-function alleles. Stroke occurred in 21 (6.3%) of 336 patients in the ticagrelor/aspirin group and 30 (8.8%) of 339 patients in the clopidogrel/aspirin group (hazard ratio 0.70; 95% confidence interval 0.40 to 1.22; P=0.20). Patients with large artery atherosclerosis in the ticagrelor/aspirin group had a lower stroke recurrence at 90 days than those in the clopidogrel/aspirin group (6.0% v 13.1%; hazard ratio 0.45, 95% confidence interval 0.20 to 0.98; P=0.04). No difference was seen in the rates of major or minor haemorrhagic events between the ticagrelor/aspirin and clopidogrel/aspirin groups (4.8% v 3.5%; P=0.42). Conclusion Patients with minor stroke or transient ischaemic attack who are treated with ticagrelor plus aspirin have a lower proportion of high platelet reactivity than those who are treated with clopidogrel plus aspirin, particularly for those who are carriers of the CYP2C19 loss-of-function allele. The results of this study should be evaluated further in large scale, phase III trials and in different populations. Trial registration Clinicaltrials.gov NCT02506140 ." @default.
• W2948570007 created "2019-06-14" @default.
• W2948570007 creator A5000645986 @default.
• W2948570007 creator A5001594817 @default.
• W2948570007 creator A5012418853 @default.
• W2948570007 creator A5014450924 @default.
• W2948570007 creator A5019560977 @default.
• W2948570007 creator A5021344058 @default.
• W2948570007 creator A5021809579 @default.
• W2948570007 creator A5023022034 @default.
• W2948570007 creator A5026274834 @default.
• W2948570007 creator A5028676753 @default.
• W2948570007 creator A5030033955 @default.
• W2948570007 creator A5040166982 @default.
• W2948570007 creator A5043614894 @default.
• W2948570007 creator A5046380471 @default.
• W2948570007 creator A5046732096 @default.
• W2948570007 creator A5050875699 @default.
• W2948570007 creator A5052898732 @default.
• W2948570007 creator A5056165846 @default.
• W2948570007 creator A5057320926 @default.
• W2948570007 creator A5074448585 @default.
• W2948570007 creator A5078248814 @default.
• W2948570007 creator A5085512975 @default.
• W2948570007 creator A5086247489 @default.
• W2948570007 date "2019-06-06" @default.
• W2948570007 modified "2023-10-18" @default.
• W2948570007 title "Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial" @default.
• W2948570007 cites W1480729244 @default.
• W2948570007 cites W1726466368 @default.
• W2948570007 cites W1936710894 @default.
• W2948570007 cites W2028938803 @default.
• W2948570007 cites W2030352776 @default.
• W2948570007 cites W2035301649 @default.
• W2948570007 cites W2061975208 @default.
• W2948570007 cites W2068493362 @default.
• W2948570007 cites W2081615170 @default.
• W2948570007 cites W2082149672 @default.
• W2948570007 cites W2086599873 @default.
• W2948570007 cites W2140501627 @default.
• W2948570007 cites W2149465085 @default.
• W2948570007 cites W2162891740 @default.
• W2948570007 cites W2164386459 @default.
• W2948570007 cites W2339795684 @default.
• W2948570007 cites W2361921955 @default.
• W2948570007 cites W2434322604 @default.
• W2948570007 cites W2460117772 @default.
• W2948570007 cites W2557260043 @default.
• W2948570007 cites W2589969741 @default.
• W2948570007 cites W2591456311 @default.
• W2948570007 cites W2592527212 @default.
• W2948570007 cites W2610498431 @default.
• W2948570007 doi "https://doi.org/10.1136/bmj.l2211" @default.
• W2948570007 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6549283" @default.
• W2948570007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31171523" @default.
• W2948570007 hasPublicationYear "2019" @default.
• W2948570007 type Work @default.
• W2948570007 sameAs 2948570007 @default.
• W2948570007 citedByCount "77" @default.
• W2948570007 countsByYear W29485700072019 @default.
• W2948570007 countsByYear W29485700072020 @default.
• W2948570007 countsByYear W29485700072021 @default.
• W2948570007 countsByYear W29485700072022 @default.
• W2948570007 countsByYear W29485700072023 @default.
• W2948570007 crossrefType "journal-article" @default.
• W2948570007 hasAuthorship W2948570007A5000645986 @default.
• W2948570007 hasAuthorship W2948570007A5001594817 @default.
• W2948570007 hasAuthorship W2948570007A5012418853 @default.
• W2948570007 hasAuthorship W2948570007A5014450924 @default.
• W2948570007 hasAuthorship W2948570007A5019560977 @default.
• W2948570007 hasAuthorship W2948570007A5021344058 @default.
• W2948570007 hasAuthorship W2948570007A5021809579 @default.
• W2948570007 hasAuthorship W2948570007A5023022034 @default.
• W2948570007 hasAuthorship W2948570007A5026274834 @default.
• W2948570007 hasAuthorship W2948570007A5028676753 @default.
• W2948570007 hasAuthorship W2948570007A5030033955 @default.
• W2948570007 hasAuthorship W2948570007A5040166982 @default.
• W2948570007 hasAuthorship W2948570007A5043614894 @default.
• W2948570007 hasAuthorship W2948570007A5046380471 @default.
• W2948570007 hasAuthorship W2948570007A5046732096 @default.
• W2948570007 hasAuthorship W2948570007A5050875699 @default.
• W2948570007 hasAuthorship W2948570007A5052898732 @default.
• W2948570007 hasAuthorship W2948570007A5056165846 @default.
• W2948570007 hasAuthorship W2948570007A5057320926 @default.
• W2948570007 hasAuthorship W2948570007A5074448585 @default.
• W2948570007 hasAuthorship W2948570007A5078248814 @default.
• W2948570007 hasAuthorship W2948570007A5085512975 @default.
• W2948570007 hasAuthorship W2948570007A5086247489 @default.
• W2948570007 hasBestOaLocation W29485700071 @default.
• W2948570007 hasConcept C126322002 @default.
• W2948570007 hasConcept C127413603 @default.
• W2948570007 hasConcept C164705383 @default.
• W2948570007 hasConcept C168563851 @default.
• W2948570007 hasConcept C188816634 @default.
• W2948570007 hasConcept C203092338 @default.
• W2948570007 hasConcept C2777628954 @default.
• W2948570007 hasConcept C2777849778 @default.
• W2948570007 hasConcept C2780645631 @default.

• next